On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA ... a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic ...

Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY ... from ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Novo Nordisk and Eli Lilly , the leaders in the highly lucrative ... to develop new obesity treatments Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright ...

Charles R. Goulding and Aaron Rofe reveal how industry leaders like Eli Lilly, Johnson & Johnson, and Roche are going all-in ...

At close: May 23 at 1:43:02 PM CST ...